A Randomized, Double-blind, Parallel Group, Multicentre Phase IIIb Study to Compare Ticagrelor With Clopidogrel Treatment on the Risk of Cardiovascular Death, Myocardial Infarction and Ischemic Stroke in Patients With Established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD)

Trial Profile

A Randomized, Double-blind, Parallel Group, Multicentre Phase IIIb Study to Compare Ticagrelor With Clopidogrel Treatment on the Risk of Cardiovascular Death, Myocardial Infarction and Ischemic Stroke in Patients With Established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD)

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Ticagrelor (Primary) ; Clopidogrel
  • Indications Cardiovascular disorders; Embolism and thrombosis; Myocardial infarction; Peripheral arterial disorders; Stroke
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms EUCLID
  • Sponsors AstraZeneca
  • Most Recent Events

    • 30 Aug 2017 Results of post hoc analysis assessing incidence of ischemic/hemorrhagic stroke and transient ischemic attack, effect of ticagrelor vs clopidogrel on the ischemic stroke endpoint, and identifying predictors of stroke presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
    • 30 Aug 2017 Results (n=5345) of analysis assessing the risk of cardiovascular endpoints in the group of patients with DM (types 1 and 2) presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
    • 30 Aug 2017 Results (n=4032) assessing the effect of Ticagrelor on clinical outcomes in patients with symptomatic peripheral artery disease and a history of coronary artery disease, presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top